Answers are grounded in this paper and cite their sources.
Intragenic tandem duplications in the FLT3 gene (FLT3-ITD) are one of the most common genetic abnormalities in acute myeloid leukemia (AML) and are associated with a poor prognosis, which has led to the introduction of new-generation FLT3 inhibitors, including quizartinib, into clinical practice as part of combination therapy regimens. Given the heterogeneity of the clonal composition of AML in terms of the proportion of FLT3-ITD-positive (FLT3-ITD(+)) and FLT3-ITD-negative (FLT3-ITD(–)) clones, the effect of FLT3 inhibition on the sensitivity of various leukemic cell subpopulations to DNA-damaging chemotherapeutic agents remains poorly understood. This study demonstrates that pretreatment of FLT3-ITD(–) THP-1 AML cells with quizaritinib at non-toxic concentrations increases their resistance to the cytotoxic effects of etoposide and topotecan, whereas no such protective effect is observed in FLT3-ITD(+) MV4-11 cells. The results obtained in this study suggest that quizaritinib, as part of combination chemotherapy, may contribute to the development of drug resistance in FLT3-ITD(–) AML subclones to DNA-damaging agents by arresting proliferation in the late G2/M phase and shifting the balance of pro- and anti-apoptotic proteins of the Bcl-2 family toward survival, a factor that must be taken into account when developing targeted therapy regimens with FLT3 inhibitors.
No takes yet. Share an insight, caveat, or question.
Krasnov et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: